These pan-cancer survival analyses indicated that PRRX1 expression was an adverse prognostic factor in patients with seven types of cancer (Figure 7A): adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uveal melanoma (UVM). This evidence concerns the gene PRRX1 and lung adenocarcinoma.